Chapter 10. Men's Health
1. U.S. Preventive Services Task Force. Recommended Preventive Services, 2007. www.ahrq.gov/clinic/pocketgd07/gcp1.htm
2. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006;91:1995-2010.
3. Edelstein D, Sivanandy M, Shahani S, Basaria S. The latest options and future agents for treating male hypogonadism. Expert Opin Pharmacother. 2007;8:2991-3008.
4. Editors of the Prescriber’s Letter and the Pharmacist’s Letter. Natural Medicines Comprehensive Database. Stockton, CA: Therapeutic Research Faculty. 2006.
5. King DS, Sharp RL, Vukovich MD, et al. Effect of oral androstenedione on serum testosterone and adaptations to resistance training in young men: a randomized controlled trial. JAMA. 1999;281:2020–2028.
6. National Library of Medicine. Medline Plus. Drugs and Supplements. www.nlm.nih.gov/medlineplus/druginfo/natural/patient-creatine.html Accessed Nov. 27, 2007.
7. Branch JD. Effect of creatine supplementation on body composition and performance: a meta-analysis. Int J Sport Nutr Exerc Metab. 2003;13:198-226.
8. Leenders N, Sherman WM, Lamb DR, et al. Creatine supplementation and swimming performance. Int J Sport Nutr. 1999;9:251-262.
9. Somers S. The Sexy Years. New York: Random House. 2004.
10. Isidori AM, Giannetta E, Gianfrilli D, Greco EA, Bonifacio V, Aversa A, Isidori A, Fabbri A, Lensi A. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf). 2005;63:381-94.
11. Mayo Clinic. Premature Ejaculation. www.mayoclinic.com/health/premature-ejaculation/DS00578/DSECTION=8 Accessed December 4, 2007.
12. Safarinejad MR. Safety and efficacy of venlafaxine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomised study. Andrologia. 2008;40:49-55.
13. Waldinger MD. Premature ejaculation: state of the art. Urol Clin North Am. 2007;34:591-9.
14. Safarinejad MR. Comparison of dapoxetine versus paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Clin Neuropharmacol. 2006;29:243-52.
15. Morales A, Barada J, Wyllie MG. A review of the current status of topical treatments for premature ejaculation. BJU Int. 2007;100:493-501.
16. Hellstrom WJ. Current and future pharmacotherapies of premature ejaculation. J Sex Med. 2006;3 Suppl 4:332-41.
17. Cavallini G, Caracciolo S, Vitali G, et al. Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology. 2004;63:641-646.
18. Gentile V, Vicini P, Prigiotti G, et al. Preliminary observations on the use of propionyl-L-carnitine in combination with sildenafil in patients with erectile dysfunction and diabetes. Curr Med Res Opin. 2004;20:1377-1384.
19. Cavallini G, Modenini F, Vitali G, et al. Acetyl-L-carnitine plus propionyl-L-carnitine improve efficacy of sildenafil in treatment of erectile dysfunction after bilateral nerve-sparing radical retropubic prostatectomy. Urology. 2005;66:1080-1085.
20. Benvenga S, Lakshmanan M, Trimarchi F. Carnitine is a naturally occurring inhibitor of thyroid hormone nuclear uptake. Thyroid. 2000;10:1043-1050.
21. Choi HK, et al. Clinical efficacy of Korean red ginseng for erectile dysfunction. Int. J Impotence Res. 1995;7:181-186.
22. Hong B, Ji YH, Hong JH, et al. A double-blind crossover study evaluating the efficacy of Korean red ginseng in patients with erectile dysfunction: a preliminary report. J Urol. 2002;168:2070-2073.
23. Wiklund IK, Mattsson LA, Lindgren R, et al. Effects of a standardized ginseng extract on quality of life and physiological parameters in symptomatic postmenopausal women: a double-blind, placebo-controlled trial. Int J Clin Pharmacol Res. 1999;19:89-99.
24. Chen J, Wollman Y, Chernichovsky T, et al. Effect of oral administration of high-dose nitric oxide donor L-arginine in men with organic erectile dysfunction: results of a double-blind, randomized placebo-controlled study. BJU Int. 1999;83:269-273.
25. AHFS Drug Information. Bethesda, MD: American Society of Hospital Pharmacists. 2000:2306-2307.
26. Luiking YC, Weusten BL, Portincasa P, et al. Effects of long-term oral L-arginine on esophageal motility and gallbladder dynamics in healthy humans. Am J Physiol. 1998;274(6 pt 1):G984-G991.
27. Riley AJ. Yohimbine in the treatment of erectile disorder. Br J Clin Pract. 1994;48:133-136.
28. Lebret T, Herve JM, Gorny P, et al. Efficacy and safety of a novel combination of L-arginine glutamate and yohimbine hydrochloride: a new oral therapy for erectile dysfunction. Eur Urol. 2002;41:608-613.
29. Braeckman J. The extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a multicenter open study. Curr Ther Res. 1994;55:776-785.
30. Romics I, Schmitz H, Frang D. Experience in treating benign prostatic hypertrophy with Sabal serrulata for one year. Int Urol Nephrol. 1993;25:565-569.
31. Marks LS, Partin AW, Epstein JI, et al. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol. 2000;163:1451-1456.
32. Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate. 1996;29:231-240.
33. Shi R, Xie Q, Gang X, Lun J, Cheng L, Pantuck A, Rao J. Effect of saw palmetto soft gel capsule on lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized trial in Shanghai,China. J Urol. 2008 Feb;179(2):610-5.
34. Champault G, Patel JC, Bonnard AM. A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. BrJ Clin Pharmacol. 1984;18:461-462.
35. Tasca A, Barulli M, Cavazzana A, et al. Treatment of obstructive symptomatology caused by prostatic adenoma using an extract of Serenoa repens. Double-blind clinical study vs. placebo [in Italian]. Minerva Urol Nefrol. 1985;37:87-91.
36. Boccafoschi C, Annoscia S. Comparison of Serenoa repens extract with placebo by controlled clinical trial in patients with prostatic adenomatosis [in Italian]. Urologia. 1983;50:1257-1268.
37. Smith HR, Memon A, Smart CJ, et al. The value of Permixon in benign prostatic hypertrophy. Br J Urol. 1986;58:36-40.
38. Descotes JL, Rambeaud JJ, Deschaseaux P, et al. Placebo-controlled evaluation of the efficacy and tolerability of Permixon in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest. 1995;9:291-297.
39. Mattei FM, Capone M, Acconcia A, et al. Serenoa repens extract in the medical treatment of benign prostatic hypertrophy [in Italian]. Urologia. 1988;55:547-552.
40. Plosker GL, Brogden RN. Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging. 1996;9:379-395.
41. Gerber GS, Kuznetsov D, Johnson BC, et al. Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology. 2001;58:960-964.
42. Willetts KE, Clements MS, Champion S, et al. Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial. BJU Int. 2003;92:267-70.
43. Bent S, Kane C, Shinohara K, et al. Saw Palmetto for Benign Prostatic Hyperplasia. N Engl J Med. 2006; 354:557-66.
44. Safarinejad MR. Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. J Herb Pharmacother. 2006;5:1-11.
45. Vontobel HP, Herzog R, Rutishauser G, et al. Results of a double-blind study on the effectiveness of ERU (extractum radicis Urticae) capsules in conservative treatment of benign prostatic hyperplasia [translated from German]. Urologe A. 1985;24:49-51.
46. Dathe G, Schmid H. Phytotherapy of benign prostate hyperplasia (BPH); double-blind study with stinging nettle root extract (Extractum Radicis Urticae - ERU) [translated from German]. Urologe B. 1987;27:223-226.
47. Lopatkin N, Sivkov A, Walther C, Schläfke S, Medvedev A, Avdeichuk J, Golubev G, Melnik K, Elenberger N, Engelmann. Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms--a placebo-controlled, double-blind, multicenter trial. World J Urol. 2005 Jun;23(2):139-46.
48. Engelmann U, Walther C, Bondarenko B, Funk P, Schläfke S. Efficacy and safety of a combination of sabal and urtica extract in lower urinary tract symptoms. A randomized, double-blind study versus tamsulosin. Arzneimittelforschung. 2006;56(3):222-9.
49. Krzeski T, Kazon M, Borkowski A, et al. Combined extracts of Urtica dioica and Pygeum africanum in the treatment of benign prostatic hyperplasia: double-blind comparison of two doses. Clin Ther. 1993;15:1011-1020.
50. Carbin BE, Eliasson R. Treatment by Curbicin in benign prostatic hyperplasia (BPH). Swed J Biol Med. 1989;2:7–9.
51. Carbin BE, Larsson B, Lindahl O. Treatment of benign prostatic hyperplasia with phytosterols. Br J Urol. 1990;66:639–41.
52. Barlet A, Albrecht J, Aubert A, et al. Efficacy of Pygeum africanum extract in the medical therapy of urination disorders due to benign prostatic hyperplasia: evaluation of objective and subjective parameters. A placebo-controlled double-blind multicenter study [translated from German]. Wien Klin Wochenschr. 1990;102:667–673.
53. Syed DN, Khan N, Afaq F, Mukhtar H. Chemoprevention of Prostate Cancer through Dietary Agents: Progress and Promise. Cancer Epidemiol Biomarkers Prev 2007;16:2193-204.
54. Helzlsouer KJ, Huang HY, Alberg AJ, et al. Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst. 2000;92:2018-2023.
55. Wright ME, Weinstein SJ, Lawson KA, et al. Supplemental and dietary vitamin E intakes and risk of prostate cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev. 2007;16:1128-1135.
56. Bjelakovic G, Nikolova D, Gluud LL, et al. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA. 2007;297:842-857.
57. Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37-46.
58. Paolisso G, D’Amore A, Giugliano D, et al. Pharmacologic doses of vitamin E improve insulin action in healthy subjects and non-insulin-dependent diabetic patients. Am J Clin Nutr. 1993;57:650-656.
59. Paolisso G, D’Amore A, Galzerano D, et al. Daily vitamin E supplements improve metabolic control but not insulin secretion in elderly type II diabetic patients. Diabetes Care. 1993;16:1433-1437.
60. Ward NC, Hodgson JM, Puddey IB, et al. Vitamin E increases blood pressure in type 2 diabetic subjects, independent of vascular function and oxidative stress. Asia Pac J Clin Nutr. 2005;14(suppl):S41.
61. Franceschi S, Bidoli E, La Vecchia C, et al. Tomatoes and risk of digestive-tract cancers. Int J Cancer. 1994;59:181-184.
62. Giovannucci E, Ascherio A, Rimm EB, et al. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst. 1995;87:1767-1776.
63. Clinton SK, Emenshiser C, Schwartz SJ, et al. cis-trans Lycopene isomers, carotenoids, and retinol in the human prostate. Cancer Epidemiol Biomarkers Prev. 1996;5:823-833.
64. Barber NJ, Zhang X, Zhu G, et al. Lycopene inhibits DNA synthesis in primary prostate epithelial cells in vitro and its administration is associated with a reduced prostate-specific antigen velocity in a phase II clinical study. Prostate Cancer Prostatic Dis. 2006;9:407-13.
65. Oh WK, Kantoff PW, Weinberg V, Jones G, Rini BI, Derynck MK, Bok R, Smith MR, Bubley GJ, Rosen RT, DiPaola RS, Small EJ. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol. 2004 Sep 15;22(18):3705-12.
66. de la Taille A, Buttyan R, Hayek O, et al. Herbal therapy PC-SPES: in vitro effects and evaluation of its efficacy in 69 patients with prostate cancer. J Urol. 2000;164:1229–1234.
67. Small EJ, Frohlich MW, Bok R, et al. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol. 2000;18:3595–3603.
68. Oh WK, George DJ, Hackmann K, et al. Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer. Urology. 2001;57:122–126.
69. Garcia-Bravo B, Rodriguez-Pichardo A, Sanchez-Pedreno P. Nickel sulphate in the treatment of alopecia areata. Contact Dermatitis. 1989;20:228–229.
70. Rhodes EL, Dolman W, Kennedy C, et al. Alopecia areata regrowth induced by Primula obconica. Br J Dermatol. 1981;104:339–340.
71. Hay IC, Jamieson M, Ormerod AD. Randomized trial of aromatherapy. Successful treatment for alopecia areata. Arch Dermatol. 1998;134:1349–1352.
72. Tritrungtasna O, Jerasutus S, Suvanprakorn P. Treatment of alopecia areata with khellin and UVA. Int J Dermatol. 1993;32:690.
73. Camacho FM, Garcia-Hernandez MJ. Zinc aspartate, biotin, and clobetasol propionate in the treatment of alopecia areata in childhood. Pediatr Dermatol. 1999;16:336–338.
74. Harrison PV, Stepanek P. Hypnotherapy for alopecia areata. Br J Dermatol. 1991;124:509–510.
75. Weindruch R, Walford R. The Retardation of Aging and Disease by Dietary Restriction. Springfield (Illinois): Charles C. Thomas. 1988. ISBN 0-398-05496-7
76. Carter CS, Hofer T, Seo AY, Leeuwenburgh C. Molecular mechanisms of life- and health-span extension: role of calorie restriction and exercise intervention. Appl Physiol Nutr Metab. 2007;32:954-66.
77. Redman LM, Heilbronn LK, Martin CK, Alfonso A, Smith SR, Ravussin E. Effect of calorie restriction with or without exercise on body composition and fat distribution. J Clin Endocrinol Metab. 2007;92:865-72.
78. Wolf OT, Neumann O, Hellhammer DH, et al. Effects of a two-week physiological dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly women and men. J Clin Endocrinol Metab. 1997;82:2363-2367.
79. Barnhart KT, Freeman E, Grisso JA, et al. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. J Clin Endocrinol Metab. 1999;84:3896-3902.
80. Flynn MA, Weaver-Osterholtz D, Sharpe-Timms KL, et al. Dehydroepiandrosterone replacement in aging humans. J Clin Endocrinol Metab. 1999;84:1527-1533.
81. van Niekerk JK, Huppert FA, Herbert J. Salivary cortisol and DHEA: association with measures of cognition and well-being in normal older men, and effects of three months of DHEA supplementation. Psychoneuroendocrinology. 2001;26:591-612.
82. Kudielka BM, Hellhammer J, Hellhammer DH, et al. Sex differences in endocrine and psychological responses to psychosocial stress in healthy elderly subjects and the impact of a 2-week dehydroepiandrosterone treatment. J Clin Endocrinol Metab. 1998;83:1756-1761.
83. Arlt W, Callies F, Koehler I, et al. Dehydroepiandrosterone supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion. J Clin Endocrinol Metab. 2001;86:4686-4692.
84. Wolf OT, Naumann E, Hellhammer DH, et al. Effects of dehydroepiandrosterone replacement in elderly men on event-related potentials, memory, and well-being. J Gerontol. 1998;53:M385-M390.
85. Dayal M, Sammel MD, Zhao J, et al. Supplementation with DHEA: Effect on Muscle Size, Strength, Quality of Life, and Lipids. J Womens Health (Larchmt). 2005;14:391-400.
86. Nair KS, Rizza RA, O’Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med. 2006;355:1647-1659.
87. Percheron G, Hogrel JY, Denot-Ledunois S, et al. Effect of 1-year oral administration of dehydroepiandrosterone to 60- to 80-year-old individuals on muscle function and cross-sectional area: a double-blind placebo-controlled trial. Arch Intern Med. 2003;163:720-727.
88. Morales AJ, Haubrich RH, Hwang JY, et al. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf). 1998;49:421-432.
89. Muller M, van den Beld AW, van der Schouw YT, et al. Effects of Dehydroepiandrosterone and Atamestane Supplementation on Frailty in Elderly Men. J Clin Endocrinol Metab. 2006;91:3988-91.
90. Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci USA. 2000;97:4279-4284.
91. Barrett-Connor E, Friedlander NJ, Khaw K-T. Dehydroepiandrosterone sulfate and breast cancer risk. Cancer Res. 1990;50:6571-6574.
92. Helzlsouer KJ, Alberg AJ, Gordon GB, et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA. 1995;274:1926-1930.
| The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. |